Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1049548

Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina


Ašić, Adna; Salazar, Ramona; Storm, Niels; Doğan, Serkan; Höppner, Wolfgang; Marjanović, Damir; Primorac, Dragan
Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina // Croatian medical journal, 60 (2019), 3; 212-220 doi:10.3325/cmj.2019.60.212 (domaća recenzija, članak, znanstveni)


CROSBI ID: 1049548 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina

Autori
Ašić, Adna ; Salazar, Ramona ; Storm, Niels ; Doğan, Serkan ; Höppner, Wolfgang ; Marjanović, Damir ; Primorac, Dragan

Izvornik
Croatian medical journal (0353-9504) 60 (2019), 3; 212-220

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
thrombophilic markers ; pharmacogenetic markers ; warfarin

Sažetak
Aim To investigate the prevalence of common genetic variants that can serve as markers of thrombophilia and warfarin pharmacogenetics in Bosnia and Herzegovina. Methods The study was performed between August and October 2017 on 130 healthy unrelated adult volunteers from Bosnian- Herzegovinian population sample. The prevalence of the following genetic variants was determined: F5 c.1601G>A (factor V Leiden), F2 c.*97G>A (factor II or prothrombin mutation), F13A1 (factor XIII) c.103G>T, MTHFR (methylenetetrahydrofolate reductase) c.665C>T and c.1286A>C, as well as PAI- 1 (plasminogen activator inhibitor 1) c.-816A>G and c.-844G>A as markers of thrombophilia risk, and *2 and *3 alleles of CYP2C9 (cytochrome P450 2C9) and five variants of VKORC1 (vitamin K epoxide reductase complex subunit 1) as markers of warfarin pharmacogenetics. DNA was isolated from buccal swabs using salting out method, while genotyping was performed using matrix-assisted laser desorption/ionization-time-offlight mass spectrometry. Results Minor allele frequencies for two main thrombophilia risk factors, F5 c.1601G>A and F2 c.*97G>A were 0.023 and 0.008, respectively. Combined data for the markers of warfarin pharmacogenetics imply that 57.4% study participants can be expected to metabolize warfarin at an extensive, 40.3% at intermediate, and 2.3% at a poor rate. Conclusion This study reports the first extensive population genetic data for thrombophilia and warfarin pharmacogenetic markers in Bosnia and Herzegovina. Allele frequencies of genetic variants are within the general average for European populations, and their presence implies the necessity of introduction of personalized medicine in warfarin- mediated antithrombotic therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Medicinski fakultet, Split,
Fakultet za dentalnu medicinu i zdravstvo, Osijek

Profili:

Avatar Url Dragan Primorac (autor)

Avatar Url Damir Marjanović (autor)

Poveznice na cjeloviti tekst rada:

doi www.ncbi.nlm.nih.gov www.cmj.hr

Citiraj ovu publikaciju:

Ašić, Adna; Salazar, Ramona; Storm, Niels; Doğan, Serkan; Höppner, Wolfgang; Marjanović, Damir; Primorac, Dragan
Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina // Croatian medical journal, 60 (2019), 3; 212-220 doi:10.3325/cmj.2019.60.212 (domaća recenzija, članak, znanstveni)
Ašić, A., Salazar, R., Storm, N., Doğan, S., Höppner, W., Marjanović, D. & Primorac, D. (2019) Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croatian medical journal, 60 (3), 212-220 doi:10.3325/cmj.2019.60.212.
@article{article, author = {A\v{s}i\'{c}, Adna and Salazar, Ramona and Storm, Niels and Do\u{g}an, Serkan and H\"{o}ppner, Wolfgang and Marjanovi\'{c}, Damir and Primorac, Dragan}, year = {2019}, pages = {212-220}, DOI = {10.3325/cmj.2019.60.212}, keywords = {thrombophilic markers, pharmacogenetic markers, warfarin}, journal = {Croatian medical journal}, doi = {10.3325/cmj.2019.60.212}, volume = {60}, number = {3}, issn = {0353-9504}, title = {Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina}, keyword = {thrombophilic markers, pharmacogenetic markers, warfarin} }
@article{article, author = {A\v{s}i\'{c}, Adna and Salazar, Ramona and Storm, Niels and Do\u{g}an, Serkan and H\"{o}ppner, Wolfgang and Marjanovi\'{c}, Damir and Primorac, Dragan}, year = {2019}, pages = {212-220}, DOI = {10.3325/cmj.2019.60.212}, keywords = {thrombophilic markers, pharmacogenetic markers, warfarin}, journal = {Croatian medical journal}, doi = {10.3325/cmj.2019.60.212}, volume = {60}, number = {3}, issn = {0353-9504}, title = {Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina}, keyword = {thrombophilic markers, pharmacogenetic markers, warfarin} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font